Augmentation of NK cell-mediated cytotoxicity to tumor cells by inhibitory NK cell receptor blockers

被引:12
作者
Tajima, K
Matsumoto, N
Ohmori, K
Wada, H
Ito, M
Suzuki, K
Yamamoto, K
机构
[1] Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan
[2] Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan
关键词
Ly49; MHC class I; mouse; peptide; phage display library;
D O I
10.1093/intimm/dxh021
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
NK cells monitor expression of MHC class I by inhibitory receptors and preferentially kill cells that lose or down-regulate MHC class I expression. One possible mechanism by which tumor cells evade NK cell killing is continued expression of appropriate MHC class I ligands to engage inhibitory receptors on NK cells. We show here that small-mol.-wt blockers against the mouse inhibitory NK cell receptor Ly49A enhance NK cell killing of such tumor cells. We identified Ly49A-binding peptides by selecting phages with the capacity to bind recombinant Ly49A expressed in Escherichia coli from a phage display random peptide library. The Ly49A-binding peptides could also bind Ly49A expressed on mammalian cells. Importantly, the Ly49A-binding peptides blocked Ly49A recognition of its MHC class I ligands H-2D(d) and H-2D(k). Moreover, blockade of Ly49A by the peptides enhanced cytotoxicity of Ly49A(+) NK cells towards H-2D(d)-expressing tumor cells. These results clearly indicate effectiveness of small-mol.-wt blockers of inhibitory NK cell receptors in enhancing NK cell-mediated killing of tumor cells that are otherwise resistant because of MHC class I expression.
引用
收藏
页码:385 / 393
页数:9
相关论文
共 49 条
[11]   Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages [J].
Diefenbach, A ;
Jamieson, AM ;
Liu, SD ;
Shastri, N ;
Raulet, DH .
NATURE IMMUNOLOGY, 2000, 1 (02) :119-126
[12]   Murine Nkg2d and Cd94 are clustered within the natural killer complex and are expressed independently in natural killer cells [J].
Ho, EL ;
Heusel, JW ;
Brown, MG ;
Matsumoto, K ;
Scalzo, AA ;
Yokoyama, WM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6320-6325
[13]  
Huard B, 2000, EUR J IMMUNOL, V30, P1665, DOI 10.1002/1521-4141(200006)30:6<1665::AID-IMMU1665>3.0.CO
[14]  
2-2
[15]   Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor [J].
Ikeda, H ;
Lethe, B ;
Lehmann, F ;
VanBaren, N ;
Baurain, JF ;
DeSmet, C ;
Chambost, H ;
Vitale, M ;
Moretta, A ;
Boon, T ;
Coulie, PG .
IMMUNITY, 1997, 6 (02) :199-208
[16]  
Johansson MH, 1998, EUR J IMMUNOL, V28, P4198, DOI 10.1002/(SICI)1521-4141(199812)28:12<4198::AID-IMMU4198>3.3.CO
[17]  
2-0
[18]   MHC CLASS-I ALLOANTIGEN SPECIFICITY OF LY-49+ IL-2-ACTIVATED NATURAL-KILLER-CELLS [J].
KARLHOFER, FM ;
RIBAUDO, RK ;
YOKOYAMA, WM .
NATURE, 1992, 358 (6381) :66-70
[19]   NK cells, MHC class I molecules and the missing self [J].
Kärre, K .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 55 (03) :221-228
[20]   Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo [J].
Koh, CY ;
Blazar, BR ;
George, T ;
Welniak, LA ;
Capitini, CM ;
Raziuddin, A ;
Murphy, WJ ;
Bennett, M .
BLOOD, 2001, 97 (10) :3132-3137